Synapse - Howard Scher

Search Within

Howard Scher

Results (139)

A physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) model of docetaxel (Doc) and neutropenia in humans

Meeting Abstract

Florian, J. A. Jr; Egorin, M. J.; Zamboni, W. C.; Eiseman, J. L.; Lagattuta, T. F.; Belani, C. P.; Chatta, G. S.; Scher, H. I.; Solit, D. B.; Parker, R. S.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Journal Article

Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; Delacruz, A.; Curley, T.; Heller, G.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

A polyvalent vaccine for high-risk prostate patients: "Are more antigens better?"

Journal Article

Slovin, S. F.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M. P.; Wilton, A.; Kelly, W. K.; Morris, M.; Solit, D.; Clausen, H.; more...
Cancer Immunology, Immunotherapy (2007)

Fulltext@MSK | Save

Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors

Journal Article

Eiseman, J. L.; Guo, J.; Ramanathan, R. K.; Belani, C. P.; Solit, D. B.; Scher, H. I.; Ivy, S. P.; Zuhowski, E. G.; Egorin, M. J.
Clinical Cancer Research (2007)

Fulltext@MSK | Save

Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin)

Meeting Abstract

Solit, D. B.; Egorin, M.; Kopil, C.; Delacruz, A.; Shaffer, D.; Slovin, S.; Morris, M.; Kelly, W. K.; Rosen, N.; Scher, H.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors

Meeting Abstract

Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

A phase I/II trial to assess tolerability and efficacy of RAD-001 with gefitinib in patients with glioblastoma multiforme and castrate metastatic prostate cancer

Meeting Abstract

Shaffer, D. R.; Abrey, L.; Beekman, K.; Morris, M.; Eicher, C.; Kelly, W. K.; Slovin, S.; Solit, D.; Rosen, N.; Scher, H. I.
EJC Supplements (2005)

Fulltext@MSK | Save

Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors

Meeting Abstract

Eiseman, J. L.; Guo, J.; Weinbaum, B.; Ramanathan, R. K.; Belani, C. P.; Solit, D. B.; Scher, H. I.; Ivy, S. P.; Zuhowski, E. G.; Egorin, M. J.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

Journal Article

Solit, D. B.; She, Y.; Lobo, J.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
Clinical Cancer Research (2005)

Fulltext@MSK | Save

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer

Journal Article

Morris, M. J.; Divgi, C. R.; Pandit-Taskar, N.; Batraki, M.; Warren, N.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Kelly, W. K.; Slovin, S.; more...
Clinical Cancer Research (2005)

Fulltext@MSK | Save